Multiple myeloma (MM) treatment is entering a “de-escalation” era: clinicians aim to preserve deep, durable disease control while lowering long-term toxicity and treatment burden. As newer, more potent options—including immunotherapies—move earlier in the disease course, the key question is no longer only how little therapy is enough to induce response, but how much is required to maintain it over time.
In a 2026 Review in Nature Reviews Clinical Oncology, Mian, Costa, Mohty and colleagues synthesize emerging evidence for multiple de-escalation strategies. The review frames de-escalation as a spectrum rather than a single approach, reflecting differences in disease biology, treatment history, and patient tolerance.
One set of strategies focuses on dose and schedule modification, aiming to reduce cumulative exposure without compromising efficacy. Another approach involves stopping one agent within a multi-drug regimen while retaining the remaining components, effectively testing whether full-intensity combination therapy is necessary for sustained control.
The authors also highlight fixed-duration treatment concepts combined with treatment-free intervals. Here, therapy duration is predefined, after which patients may enter observation—an approach that attempts to balance remission durability against reduced continuous therapy exposure.
Minimal residual disease (MRD)–adapted strategies represent a more biologically driven pathway. By using sensitive MRD testing, trials can tailor escalation or de-escalation based on measurable residual tumor burden, potentially sparing patients from overtreatment.
Two additional de-escalation candidates receive attention: omission of autologous stem cell transplantation and the use of a single infusion of chimeric antigen receptor T cells rather than repeated dosing. These approaches could reduce procedure- and resource-intensive treatment steps in selected patients.
Despite this momentum, the review notes major uncertainties. Monitoring intensity, the triggers for retreatment, and practical feasibility across diverse care settings remain unresolved. The balance between false reassurance from MRD-negative status and the risk of relapse after therapy reduction is particularly challenging.
Finally, methodological and implementation issues loom large. Selecting appropriate endpoints—durability of response, survival, toxicity, and quality of life—will shape trial success. The authors emphasize the need for carefully designed clinical trials, integration of correlative translational studies, and sustainable funding models that align stakeholders.
Translating de-escalation from concept to routine practice will require coordinated input from researchers, clinicians, regulators, patients, and payers. As contemporary trials increasingly specify which patient groups and which regimen elements are most “de-escalable,” future evidence may redefine MM treatment goals from maximal intensity toward optimized, individualized minimal effective therapy.
Subject of Research: Multiple myeloma de-escalation strategies; optimizing treatment intensity and duration
Article Title: De-escalation trials in multiple myeloma: past, present and future.
Article References: Mian, H., Costa, L.J., Mohty, M. et al. De-escalation trials in multiple myeloma: past, present and future. Nat Rev Clin Oncol (2026). https://doi.org/10.1038/s41571-026-01186-3
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41571-026-01186-3
Keywords: de-escalation, multiple myeloma, immunotherapy, MRD, treatment-free interval, dose/schedule modification, CAR T-cell, autologous stem cell transplantation
